Menu

Neuropharmacologist Arvid Carlsson Dies at 95

The Nobel laureate’s discoveries led to a treatment for Parkinson’s disease.

Jul 2, 2018
Sukanya Charuchandra
Arvid Carlsson
WIKIMEDIA, VOGLER

Arvid Carlsson, a Swedish pharmacologist whose discovery of dopamine’s role in Parkinson’s disease revolutionized research into the condition, died on June 29. He was 95.

“Arvid Carlsson is the originator of several major discoveries that led to dramatic improvements in quality of life for millions of patients with neurological and psychiatric disorders,” Agneta Holmäng, dean of the Sahlgrenska Academy, says in a statement from the University of Gothenburg, where Carlsson was an emeritus professor of pharmacology.

Born into an academic family in Uppsala, Sweden, in 1923, he began studying medicine at the University of Lund in 1941. Carlsson completed his medical and doctoral degrees in 1951. During that period, he served in the Swedish military forces on-and-off for two years. In 1959, he became a professor of pharmacology at the University of Lund.

Prior to Carlsson’s research into dopamine, the scientific community believed the molecule was merely responsible for the formation of norepinephrine. His work, in 1957, with rabbits that exhibited movement difficulties revealed dopamine’s role in and led to the development of therapies for the neurodegenerative disorder Parkinson’s disease. Carlsson used L-dopa, a precursor of dopamine, to treat the rabbits. This compound is now used to ameliorate Parkinson’s symptoms in patients.

In 2000, Carlsson won the Nobel Prize in Physiology or Medicine for this work. “The award that you get from patients, compared to all the awards I have received, is much more important,” Carlsson said in a podcast recorded for the Sahlgrenska Academy in 2016.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.
Corning Introduces New 1536-well Spheroid Microplate
Corning Introduces New 1536-well Spheroid Microplate
High-throughput spheroid microplate benefits cancer research, drug screening